Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beatriz Rey

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Cancers|March 11, 2023
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple MyelomaBorja Puertas, Verónica González-Calle, Eduardo Sobejano-Fuertes, et al.
Therapeutic Advances in Hematology|October 6, 2022
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMDLaura Vilorio-Marqués, Christelle Castañón Fernández, Elvira Mora, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2024
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO GroupBeatriz Rey-Búa, Carlos Grande, José J Sánchez Blanco, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2025
Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell TransplantationBorja Puertas, Elena Alejo, José J Pérez-Morán, et al.
Haematologica|April 27, 2023
Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patientsBorja Puertas, Verónica González-Calle, Anna Sureda, et al.
Journal for Immunotherapy of Cancer|March 6, 2026
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myelomaMagdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, et al.
British Journal of Haematology|June 18, 2026
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survivalBorja Puertas, Irene Padilla, Elena Alejo, et al.
American Journal of Hematology|November 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapyAintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, et al.
Thrombosis and Haemostasis|December 24, 2025
Optimizing Surgical Approaches for Patients with Inherited Factor VII DeficiencyPablo García-Jaén, José Manuel Martín de Bustamante, Ana Mendoza-Martínez, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Cancers|March 11, 2023
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple MyelomaBorja Puertas, Verónica González-Calle, Eduardo Sobejano-Fuertes, et al.
Therapeutic Advances in Hematology|October 6, 2022
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMDLaura Vilorio-Marqués, Christelle Castañón Fernández, Elvira Mora, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2024
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO GroupBeatriz Rey-Búa, Carlos Grande, José J Sánchez Blanco, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2025
Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell TransplantationBorja Puertas, Elena Alejo, José J Pérez-Morán, et al.
Haematologica|April 27, 2023
Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patientsBorja Puertas, Verónica González-Calle, Anna Sureda, et al.
Journal for Immunotherapy of Cancer|March 6, 2026
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myelomaMagdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, et al.
British Journal of Haematology|June 18, 2026
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survivalBorja Puertas, Irene Padilla, Elena Alejo, et al.
American Journal of Hematology|November 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapyAintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, et al.
Thrombosis and Haemostasis|December 24, 2025
Optimizing Surgical Approaches for Patients with Inherited Factor VII DeficiencyPablo García-Jaén, José Manuel Martín de Bustamante, Ana Mendoza-Martínez, et al.
Pageof 5